This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

"With these strategic priorities in place, we also have defined operational priorities to ensure we deliver results in the short term. These address innovation, global reach and execution," Kullman said.

Kullman stressed that increasing DuPont's return on research and development is a top priority, noting that "science is at the core of who we are as a company. Science enables our growth, differentiates us and gives us competitive advantage.

"We stand on a strong foundation of scientific capability and market knowledge," Kullman told investors. "We leverage these strengths across our portfolio of businesses to find new growth opportunities. At the same time, we continually evaluate the ability of each business to contribute to our overall value creation goals for our shareholders and we determine the right path forward."

The company reported that its long-term growth targets are 7 percent average annual sales growth and 12 percent average annual operating earnings per share growth for the coming years.

DuPont Executive Vice President and Chief Financial Officer
Nicholas C. Fanandakis noted that the company has taken steps to ensure that its growth targets are aligned with current market realties. He presented updated revenue growth, long-term sales and margin-growth targets for each DuPont business segment.

"We run a rigorous and disciplined resource allocation process," said Fanandakis. "We will continue to invest differentially across the portfolio in our most promising value creation opportunities."